Abstract
γ-Secretase is responsible for the final cut of the amyloid β-peptide (Aβ) precursor (APP) to produce the Aβ peptide implicated the pathogenesis of Alzheimers disease (AD). Thus, this protease is a top target for the development of AD therapeutics. γ-Secretase is a complex of four different integral membrane proteins, with the multi-pass presenilin being the catalytic component of a novel intramembrane-cleaving aspartyl protease. γ-Secretase cleaves other substrates besides APP, the most notorious being the Notch receptor that is required for many cell differentiation events. Because proteolysis of Notch by γ-secretase is essential for Notch signaling, interference with this process by γ-secretase inhibitors can cause severe toxicities. Thus, the potential of as therapeutic target likely depends on the ability to selectively inhibit Aβ production without hindering Notch proteolysis. The discovery of compounds capable of such allosteric modulation of the protease activity has revived γ-secretase as an attractive target. Structural modification of these secretase modulators through medicinal chemistry should lead to in vivo active agents suitable for clinical trials.
Keywords: Alzheimers disease, Presenilins, Janus kinase 3, COX inhibitors, Amyloid beta
Current Alzheimer Research
Title: γ-Secretase Modulators
Volume: 4 Issue: 5
Author(s): Michael S. Wolfe
Affiliation:
Keywords: Alzheimers disease, Presenilins, Janus kinase 3, COX inhibitors, Amyloid beta
Abstract: γ-Secretase is responsible for the final cut of the amyloid β-peptide (Aβ) precursor (APP) to produce the Aβ peptide implicated the pathogenesis of Alzheimers disease (AD). Thus, this protease is a top target for the development of AD therapeutics. γ-Secretase is a complex of four different integral membrane proteins, with the multi-pass presenilin being the catalytic component of a novel intramembrane-cleaving aspartyl protease. γ-Secretase cleaves other substrates besides APP, the most notorious being the Notch receptor that is required for many cell differentiation events. Because proteolysis of Notch by γ-secretase is essential for Notch signaling, interference with this process by γ-secretase inhibitors can cause severe toxicities. Thus, the potential of as therapeutic target likely depends on the ability to selectively inhibit Aβ production without hindering Notch proteolysis. The discovery of compounds capable of such allosteric modulation of the protease activity has revived γ-secretase as an attractive target. Structural modification of these secretase modulators through medicinal chemistry should lead to in vivo active agents suitable for clinical trials.
Export Options
About this article
Cite this article as:
Wolfe S. Michael, γ-Secretase Modulators, Current Alzheimer Research 2007; 4 (5) . https://dx.doi.org/10.2174/156720507783018299
DOI https://dx.doi.org/10.2174/156720507783018299 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Yoga can Alter the Autonomic Neural Activity: A Critical Analysis
Current Traditional Medicine From Peptides to Small Molecules: An Intriguing but Intricated Way to New Drugs
Current Medicinal Chemistry The Role of Notch Signaling Pathway in Epithelial-Mesenchymal Transition (EMT) During Development and Tumor Aggressiveness
Current Drug Targets The Structural Details of Aspirin Molecules and Crystals
Current Medicinal Chemistry PET Radiopharmaceuticals for Personalized Medicine
Current Drug Targets Therapeutic Noninvasive Brain Stimulation in Alzheimer’s Disease
Current Alzheimer Research Quantitative Proteomics with Isotope Dilution Analysis: Principles and Applications
Current Proteomics Blood Brain Barrier Compromise with Endothelial Inflammation may Lead to Autoimmune Loss of Myelin during Multiple Sclerosis
Current Neurovascular Research Inhibitors of Phosphoinositol 3 Kinase and NFκB for the Treatment of Chronic Obstructive Pulmonary Disease
Recent Patents on Inflammation & Allergy Drug Discovery Development of Novel Amyloid Imaging Agents Based Upon Thioflavin S
Current Alzheimer Research Discovering the Potentials of Medicinal Mushrooms in Combating Depression – A Review
Mini-Reviews in Medicinal Chemistry Recent Advances in Transcranial Focused Ultrasound (FUS) Triggered Brain Delivery
Current Drug Targets Current Issues in Tumor Immunology
Current Bioinformatics Nutrition and Bone Health: Its Relationship to Osteoporosis
Current Nutrition & Food Science Genomics and the Prospects of Existing and Emerging Therapeutics for Cardiovascular Diseases
Current Pharmaceutical Design Retinoids as Differentiating Agents in Oncology: A Network of Interactions with Intracellular Pathways as the Basis for Rational Therapeutic Combinations
Current Pharmaceutical Design Preparation and Characterization of Bifunctional Nanoparticles of Vitamin E TPGS-emulsified PLGA-PEG-FOL Containing Deferasirox
Nanoscience & Nanotechnology-Asia Therapeutic Potential of Cannabinoids in Trigeminal Neuralgia
Current Drug Targets - CNS & Neurological Disorders Current Status and Future Directions of Nanoparticulate Strategy for Cancer Immunotherapy
Current Drug Metabolism Editorial (Thematic Issue: An Overwiew on the Chemistry and Biochemistry of Triterpenoids)
Mini-Reviews in Organic Chemistry